DuraGraft Registry 005-01
Research type
Research Study
Full title
European Multi-Center Registry to Assess Outcomes in Patients Undergoing Coronary Artery Bypass Graft Surgery: Treatment of Vascular Conduits with DuraGraft®, a Novel Endothelial Damage Inhibitor
IRAS ID
220980
Contact name
Vilas Satishchandran
Contact email
Sponsor organisation
Somahlution
Clinicaltrials.gov Identifier
Duration of Study in the UK
5 years, 6 months, 1 days
Research summary
DuraGraft® is a solution that is used to help preserve and protect blood vessels during coronary artery bypass grafting (CABG) surgery.
The DuraGraft® Registry is a European registry of patients who have undergone CABG and whose vascular grafts have been treated with DuraGraft®.
The DuraGraft Registry will collect pre-CABG intraoperative and post-operative data, major post-CABG cardiovascular adverse events, health economic outcomes and patient reported quality of life over a period of 5 years.
This registry has been designed to collect additional medical information about the safety and performance of DuraGraft®.
REC name
London - Surrey Research Ethics Committee
REC reference
17/LO/0456
Date of REC Opinion
12 Apr 2017
REC opinion
Further Information Favourable Opinion